Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol (LDL-C) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patients with Very High Triglycerides (>500 mg/dL) Results Support Upcoming Submission by Partner, Edding, Seeking Regulatory Approval in China DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today shared positive, statistically […]

VASCEPA®, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events (MACE) in post hoc exploratory analyses of patients with a history of CABG by 24% and 36%, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 31% Administration of VASCEPA resulted in […]

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Eight Presentations, Including REDUCE-IT® CABG (Coronary Artery Bypass Graft) Results and Additional Mechanism of Action Insights DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that new scientific findings that add […]

Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT REDUCE-IT patients with decreased renal function prior to treatment showed similarly favorable relative risk reductions and numerically greater absolute risk reductions in cardiovascular events in […]

VASCEPA®, compared with placebo, significantly reduced primary composite first and total MACE (major adverse cardiovascular events) in post hoc exploratory analyses of patients with a history of PCI by 34% and 39%, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 34% Administration of VASCEPA resulted in robust absolute risk reductions of 8.5% and 5.4% and numbers needed to treat (NNT) of 12 and 19, respectively, for both […]

VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients VASCEPA in REDUCE-IT® cardiovascular outcomes study achieved statistical significance for primary and secondary endpoints at predefined blinded first and second interim analyses that persisted at final analyses VASCEPA […]